Nivolumab for the treatment of non-clear cell renal cell carcinoma
A retrospective study has proven the effectiveness and tolerability of [...]
A retrospective study has proven the effectiveness and tolerability of [...]
Despite significant improvements in the treatment outcomes of clear cell [...]
Patients diagnosed with a rare kidney cancer are often treated [...]
Chi-Med (Hutchinson Pharma), a Hong Kong-based biotechnology company, and AstraZeneca [...]
This video interview summarises treatments in development for papillary renal [...]
A recent paper published in European Urology has characterised the [...]
This article discusses five potential risk factors for kidney cancer, [...]
Nivolumab has demonstrated a substantial objective response rate and was [...]
Renal medullary carcinoma is a very rare subtype of renal [...]
In this video, Dr W. Marston Linehan, chief of the [...]